Buscar en
Cirugía Española (English Edition)
Toda la web
Inicio Cirugía Española (English Edition) Prognostic value of the nodal ratio in gastric cancer: unicentric analysis of 19...
Journal Information
Vol. 100. Issue 5.
Pages 266-273 (May 2022)
Original article
Full text access
Prognostic value of the nodal ratio in gastric cancer: unicentric analysis of 199 patients
Valor pronóstico del ratio nodal en el cáncer gástrico: análisis unicéntrico de 199 pacientes
Ibabe Villalabeitia Atecaa,
Corresponding author
, Arkaitz Perfecto Valeroa, Clara Serrano Hermosillaa, Ainhoa Marcaida Salazara,c, Silvia Pérez Fernándezb, Aingeru Sarriugarte Lasartea,b,c
a Cirugía General y Aparato Digestivo, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain
b Instituto de Investigación Sanitaria Biocruces, Barakaldo, Vizcaya, Spain
c UPV/EHU Universidad del País Vasco/Euskal Herriko Unibertsitatea, Barakaldo, Vizcaya, Spain
This item has received
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (4)
Table 1. Demographic data and pathologic factors.
Table 2. Univariate study of survival of the lymphatic dissemination classification systems.
Table 3. Multivariate study of overall survival of lymph node staging systems.
Table 4. Comparison of the prognostic value of the different staging systems and comparison among the 3 systems using Δ AUC.
Show moreShow less

In the gastric cancer the most widely used classification is the AJCC TNM system. However, it presents limitations, such as staging migration in cases with suboptimal lymphadenectomies. The nodal ratio has been proposed as an alternative system, proving to be a good prognostic predictor of survival. The aim was to assess the influence of the nodal ratio measured in tertiles [tNR] as a prognostic factor and compare with the TNM systems (7th ed.) and log odds of positive lymph nodes [LODDS].

Material and methods

Retrospective and single-center study on 199 patients operated on with curative intent between 2010 and 2014. For each system an univariate and multivariate analysis was performed and the overall survival rates [OS] were compared by the ROC test.


The prognostic factors that showed statistical significance in the multivariate analysis were: tRN2 (HR2.87) and tRN3 (HR7.29); LODDS 2 (HR1.55), LODDS3 (HR2.6) and LODDS4 (HR4.9); pN2 (HR1.84) and pN3 (HR2.91). The 5-year OS was 75.8%, 61.4%, 25.8%, and 3.84% for tRN0, tRN1, tRN2 and tRN3; 72.4%, 60%, 29.1% and 13.9% for LODDS1, LODDS2, LODDS3 and LODDS4; and 77.6%, 59.4%, 28.8% and 25.5% for pN0, pN1, pN2 and pN3, respectively. The three systems behaved as good predictors, with areas under the curve >0.75.


tNR was an independent prognostic factor for estimating survival in gastric cancer. Furthermore, the ease of its calculation in clinical practice could reduce the effect of staging migration.

Lymph node ratio
Lymph node metastasis
Gastric cancer
Prognostic factor

El sistema de clasificación ganglionar gástrico más utilizado en el cáncer gástrico es el TNM. No obstante presenta limitaciones, como la “migración de estadiaje” en los casos con linfadenectomías subóptimas, por ello se han planteado distintos sistemas. Asimismo, el objetivo fue valorar la influencia del ratio nodal medido en terciles [RNt] como factor pronóstico, y compararlo con los sistemas TNM (7ª ed.) y log odds of positive lymph nodes [LODDS].

Material y métodos

Se trata de un estudio retrospectivo y unicéntrico sobre 199 pacientes con neoplasia gástrica intervenidos con intención curativa entre 2010 y 2014. Se realizó un análisis univariante y multivariante de cada sistema, y se compararon las tasas de supervivencia global [SG] obtenidas mediante test ROC.


Los factores pronóstico que mostraron significación estadística en el análisis multivariante fueron: RNt2 (HR2,87) y RNt3 (HR7,29); LODDS 2 (HR1,55), LODDS3 (HR2,6) y LODDS4 (HR4,9); pN2 (HR1.84) y pN3 (HR2.91). La SG a 5 años fue del 75,8%, 61,4%, 25,8% y 3,84% para RNt0, RNt1, RNt2 y RNt3; 72,4%, 60%, 29,1% y 13,9% para LODDS1, LODDS2, LODDS3 y LODDS4; y 77,6%, 59,4%, 28,8% y 25,5% para pN0, pN1, pN2 y pN3, respectivamente. Los tres sistemas se comportaron como buenos predictores, con áreas bajo la curva >0,75.


El RNt fue un factor pronóstico independiente para la estimación de la supervivencia en el cáncer gástrico. Además, la facilidad de su cálculo en la práctica clínica podría disminuir el efecto de migración de estadificación.

Palabras clave:
Ratio nodal
Afectación ganglionar
Cáncer gástrico
Factor pronóstico
Full Text

Lymph node involvement is one of the most important prognostic factors in gastric cancer. The pathological N category (pN) is the most widely used in staging1; however, its main limitation is the influence of the number of resected lymph nodes. Thus, some cases with suboptimal lymphadenectomies (less than 15 lymph nodes analyzed) may have a ‘stage migration’ effect.2,3

The lymph node ratio (LNR), which is the number of metastatic lymph nodes among the total number of resected lymph nodes, has been proposed as an alternative to the Tumor-Node-Metastasis (TNM) lymph node classification system due to its good predictive value and its ease of application.4,5

In addition, the log odds of positive lymph nodes (LODDS) system, which is based on the logarithm of the positive lymph nodes among the negative nodes analyzed, has been shown to be the best prognostic predictor to estimate the survival of this cancer.4 However, its clinical application is not very reproducible due to the complexity of its calculation and interpretation: log (pnod + 0.5)/(tnod − pnod + 0.5), where pnod refers to the number of positive nodes and tnod to the total number of resected nodes; +0.5 is added to both the numerator and the denominator to avoid results that tend to infinity.6

The objective of this study was to assess the influence of LNR as a prognostic factor in gastric cancer, and to compare it with the classical staging system (TNM pN category) and the LODDS.


The methodology was based on a retrospective study of a prospective series of patients from a single hospital who underwent surgery with curative intent for gastric cancer between January 1, 2010 and December 31, 2014. Follow-up continued until December 31, 2019. Patients with metastatic disease in the pathology analysis (pM+) and those who died in the first 120 postoperative days were excluded.

Data was collected retrospectively by reviewing medical records, specifically analyzing the variables under study: demographic, surgical, pathological and prospective follow-up.

All patients diagnosed with gastric neoplasm were evaluated by a multidisciplinary committee. Total or partial gastrectomy was indicated individually depending on the extension, histology and location of the tumor. D2 lymphadenectomy was performed in a standardized manner and later extended to the D1 region in patients of advanced age or with comorbidities.

Tumors were classified during the study period according to the current TNM system of the American Joint Committee on Cancer (AJCC), 7th Edition, 2010. All patients were reassessed by the medical oncology service to estimate the need for adjuvant treatments. A joint follow-up was established between the gastrointestinal surgery and medical oncology services (scheduled every 6 months for 5 years), with alternating lab work and radiological and/or gastroscopic follow-up. Patients who presented disease recurrence underwent individualized follow-up that lasted until survival, death, or cure.

The cut-off points for LNR were established in tertiles in order to homogenize the number of patients included in each subgroup. The LODDS system was based on the classification proposed by Jian-Hui, et al.: LODDS1 < −1.5; −1.5 < LODDS2< −1; −1 < LODDS3 < 0; and LODDS4 > 0.4

Informed consent was obtained from all patients undergoing surgery in order to use the information derived for teaching or research purposes. The study was approved by the Clinical Research Ethics Committee of the OSI Ezkerraldea-Enkarterri-Cruces (CEIC E20/14).

Statistical analysis

Quantitative variables were described using the median and range or mean and its standard deviation, while qualitative variables were described as percentages. Five-year overall survival (OS) was calculated, which was defined as the time interval between the date of the intervention and the date of death or last follow-up. The percentages of 5-year survivors were presented and compared with the percentages of 5-year deaths using the chi-square test. Kaplan-Meier curves were made to compare OS according to each lymph node classification: a) LNR expressed in tertiles (tNR): tNR0 = 0; tNR1 > 0 ≤ 0.33; tNR2 > 0.33 ≤ 0.66; and tNR3 > 0.66; b) TNM classification (AJCC, 7th Ed, 2010): pN0 = 0 nodes, pN1 = 1–2; pN2 = 3–6; pN3 > 6); and c) LODDS system: LODDS1 < −1.5, −1.5 < LODDS2 < −1, −1 < LODDS3 < 0, and LODDS4 > 0. A univariate analysis of the categories of each classification and a multivariate analysis with Cox regression models were performed, adding these same variables and age (≤65 or >65 years), as well as the location (according to the gastroscopy) and pathological T (according to TNM) as adjustment variables. To measure the discrimination capacity of the models, we calculated the area under the curve (AUC), in addition to comparing which of the models demonstrated better discrimination capability by calculating the difference in AUC (Δ AUC).

For the study of the requirements to be considered in the classification systems, the following were analyzed: (1) Monotonicity, evaluating the proportional increase obtained by the hazard ratio (HR) or the relative risk in the multivariate analysis; (2) Homogeneity, analyzing the range of the confidence interval; and (3) Differentiation, quantified by superimposing the survival intervals of each stage according to Kaplan–Meier graphs.2

All analyses were performed with the statistical program R (version 4.0.1): A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria). P values <.05 were considered statistically significant.


A total of 222 patients underwent surgery with curative intent. Fourteen subjects were excluded due to the presence of pM + and 9 due to death in the first 120 days after surgery or due to loss of follow-up (Fig. 1).

Fig. 1.

Flow diagram of the patient selection process.


In the end, 199 patients were included in the study. The main demographic data and pathological factors are shown in Table 1. Lymphadenectomies of ≥15 lymph nodes were performed in 109 patients (55.9%), while lymph node resection was considered suboptimal in 86 cases (44.1%). In the univariate analysis, the following were statistically significant prognostic factors for survival: age >65 years, diffuse histology, moderately and poorly differentiated or undifferentiated tumors, categories T3–4, categories pN2−3, tNR 2–3 and LODDS 3–4 (Table 2).

Table 1.

Demographic data and pathologic factors.

Variables  Patients (%) 
Categorical age
≤65 years  76 (38.2) 
>65 years  123 (61.8) 
Males  134 (67.3) 
Females  65 (32.7) 
Location (gastroscopy)
Superior 1/3  39 (19.6) 
Body  54 (27.1) 
Antrum  106 (53.3) 
Lauren histology
Intestinal adenocarcinoma  82 (42.7) 
Diffuse  63 (32.8) 
Indeterminate  47 (24.5) 
Degree of differentiation
Well-differentiated  47 (25.7) 
Moderately differentiated  45 (24.6) 
Poorly differentiated or non-differentiated  91 (49.7) 
T pathologic (TNM)
  25 (12.6) 
pT2  40 (20.1) 
pT3  94 (47.2) 
pT4  40 (20.1) 
N pathologic (TNM)
pN0  58 (28.6) 
pN1  37 (18.9) 
pN2  52 (26.5) 
pN3a/pN3b  51 (26.0) 
tNR0  58 (29.1) 
tNR1  57 (28.6) 
tNR2  58 (29.1) 
tNR3  26 (13.1) 
LODDS1  87 (45.1) 
LODDS2  15 (7.77) 
LODDS3  55 (28.5) 
LODDS4  36 (18.7) 
Resected lymph nodes
<15 nodes  86 (44.1) 
≥15 nodes  109 (55.9) 
D1  124 (63.6) 
D2  71 (36.4) 

LODDS, log odds of positive lymph nodes; tNR, node ratio expressed with tertiles; pN, pathologic category N; LNR, lymph node ratio; TNM, tumor-node-metastasis.

Table 2.

Univariate study of survival of the lymphatic dissemination classification systems.

  Overall survival 
Variables  HR (95%CI) P value 
Categorical age
≤65 years  Ref. 
>65 years  1.54 (1.05−2.24) .027 
Males  Ref. 
Females  0.93 (0.63−1.35) .689 
Location (gastroscopy)
Upper third  Ref. 
Body  0.59 (0.35−1.00) .049 
Antrum  0.67 (0.43−1.05) .080 
Lauren histology
Intestinal adeno.  Ref. 
Diffuse  1.61 (1.05−2.47) .028 
Indeterminate  1.32 (1.05−2.47) .243 
Degree of differentiation
Well differentiated  Ref. 
Moderately diff.  1.86 (1.02−3.38) .041 
Poorly diff. or undiff.  2.56 (1.52−4.32) <.001 
T pathologic (TNM)
p T2  1.48 (0.60−3.64) .389 
pT3  3.74 (1.71−8.17) .001 
pT4  7.93 (3.49−18.0) <.001 
N pathologic (TNM)
pN0  Ref. 
pN1  1.55 (0.82−2.93) .181 
pN2  3.21 (1.88−5.49) <.001 
pN3a/pN3b  4.41 (2.59−7.50) <.001 
tNR0  Ref. 
tNR1  1.25 (0.71−2.21) .433 
tNR2  3.66 (2.21−6.06) <.001 
tNR3  10.3 (5.66−18.8) <.001 
LODDS1  Ref. 
LODDS2  1.48 (0.65−3.34) .349 
LODDS3  3.38 (2.14−5.34) <.001 
LODDS4  5.98 (3.64−9.85) <.001 
Resected lymph nodes
<15 nodes  Ref. 
≥15 nodes  0.81 (0.56−1.16) .241 
D1  Ref. 
D2  0.97 (0.65−1.44) .877 

HR, hazard ratio; 95%CI, 95% confidence interval; LODDS, log odds of positive lymph nodes; tNR, node ratio expressed in tertiles; pN, pathologic category N; LNR, lymph node ratio; TNM, tumor-node-metastasis system.

In the multivariate analysis, the tNR system was shown to be an independent prognostic factor for survival: HR for tNR2: 2.87 (1.57–5.25) and HR for tNR3: 7.29 (3.6−14.73) (Table 3). The 5-year OS estimate was 75.8% for tNR0; 61.4% para tNR1; 25.8% para tNR2; and 3.84% para tNR3 (Fig. 2A).

Table 3.

Multivariate study of overall survival of lymph node staging systems.

Variables  Multivariate analysis  2 multivariate analysis  3 multivariate analysis 
  HR (95%CI) P value  HR (95%CI) P value  HR (95%CI) P value 
Age  1.82 (1.22−2.71) .004  1.80 (1.21−2.68) .004  1.86 (1.24−2.79) .003 
Body  0.52 (0.31−0.90) .019  0.71 (0.41-1.22) .214  0.51 (0.29−0.89) .018 
Antrum  0.75 (0.47−1.19) .22  0.90 (0.56−1.44) .66  0.79 (0.5−1.26) .326 
pT2  1.1 (0.44−2.76) .844  0.93 (0.36−2.42) .888  0.93 (0.36−2.37) .874 
pT3  2.15 (0.91−5.05) .08  2 (0.84−4.75) .116  2.03 (0.9−4.59) .09 
pT4a/T4b  4.22 (1.67−10.65) .002  3.61 (1.43−9.09) .006  4.12 (1.71−9.91) .002 
N patho. (TNM)
pN0  Ref.     
pN1  1.41 (0.72−2.74) 0.313     
pN2  1.84 (1−3.38) 0.05     
pN3a/pN3b  2.91 (1.59−8.33) <0.001     
tNR0    Ref.   
tNR1    1.11 (0.59−2.11) 0.739   
tNR2    2.87 (1.56−5.25) <0.001   
tNR3    7.29 (3.6−14.73) <0.001   
LODDS1      Ref. 
LODDS2      1.55 (0.66−3.64) 0.315 
LODDS3      2.6 (1.6−4.2) <0.001 
LODDS4      4.9 (2.86−8.38) <0.001 

HR, hazard ratio; 95%CI, 95% confidence interval; LODDS, log odds of positive lymph nodes; tNR, node ratio expressed in tertiles; pN, pathologic category N; LNR, lymph node ratio; TNM, tumor-node-metastasis system.

Fig. 2.

Kaplan–Meier curves for overall survival of the staging systems: (A) According to the pN classification of the TMN; (B) According to the lymph node ratio expressed with tertiles; (C) According to LODDS.


The LODDS system was also shown to be an independent prognostic factor in the multivariate survival analysis (Table 3): HR for LODDS2: 1.55 (0.66−3.64); LODDS3: 2.6 (1.6−4.2); and LODDS4: 4.9 (2.86−8.38). Thus, the 5-year survival rate was 72.4% for LODDS1, 60% for LODDS2, 29.1% for LODDS3, and 13.9% for LODDS4 (Fig. 2B).

Likewise, the pN category of the classic TNM system was shown to be an independent prognostic factor in the multivariate survival analysis (Table 2): HR for pN2: 1.84 (1−3.38), and HR for pN3: 2.91 (1.59−8.33). The 5-year survival according to this system was 77.6% for pN0, 59.4% for pN1, 28.8% for pN2, and 25.5% for pN3 (Fig. 2C).

In the present cohort, the 3 assessment systems for lymph node involvement can be considered good prognostic predictors according to the ROC curves, with AUC close to 0.75 (Table 4). In the specific assessment of the patients with suboptimal lymphadenectomies, the LODDS system obtained the best score, with an AUC = 0.752. Likewise, the tNR systems and the pN category of the TNM showed similar values: AUC = 0.744 and 0.74, respectively (Table 4). Similarly, the 3 models were compared by calculating the Δ AUC, as shown in Table 4.

Table 4.

Comparison of the prognostic value of the different staging systems and comparison among the 3 systems using Δ AUC.

  ROC test  95%CI 
N pathologic (TNM 7th Ed)  0.735  0.694−0.776 
tNR  0.766  0.728−0.804 
LODDS  0.76  0.722−0.799 
<15 nodes
N pathologic (TNM)  0.74  0.681−0.798 
tNR  0.744  0.686−0.803 
LODDS  0.752  0.692−0.812 
15 nodes
N pathologic (TNM)  0.761  0.704−0.817 
tNR  0.788  0.736−0.84 
LODDS  0.777  0.726−0.829 
pN system (TNM)  LNR  LODDS 
pN (TNM)  P = .675  P = .351 
LNR  Δ = 0.005  P = .543 
LODDS  Δ = 0.013  Δ = 0.008 

AUC, area under curve; 95%CI, 95% confidence interval; LODDS, log odds of positive lymph nodes; tNR, node ratio expressed in tertiles; pN, pathologic category N; ROC, receiver operating characteristic curve; LNR, lymph node ratio; TNM, tumor-node-metastasis system.

Finally, regarding monotonicity, homogeneity and differentiation capacity, the results were as follows: 1) Monotonicity of the pN category of the TNM: pN1 = HR1.84; pN2 = HR2.75; pN3 = HR6.23; for LNR (tNR0 = HR0.9, tNR1 = HR2.36, tNR3 = HR6.17); and from the LODDS: LODDS2 = HR1.55, LODDS3 = HR2.6, LODDS4 = HR4.9; 2) TNM system homogeneity: pN0 = 28.6%; pN1 = 18.9%; pN2 = 26.5%; and pN3 = 26.0%; for tNR: tNR0 = 29.1%, tNR1 = 28.6%, tNR3 = 13.1%; and for LODDS: LODDS1 = 45.1%, LODDS2 = 7.77%, LODDS3 = 28.5%, LODDS4 = 18.7%, and 3). Discrimination ability is shown in Fig. 2.


Lymph node spread is one of the most important prognostic factors in gastric cancer and has a great impact on survival. According to the latest edition of the clinical practice guidelines of the National Comprehensive Cancer Network (NCCN), standardized D2 lymphadenectomy is recommended.6 However, various studies show that in large Western and Asian cohorts, this type of lymph node resection was only performed in 29% and 60.2% of cases, respectively.7,8 This often leads to a suboptimal lymph node resection rate (<15 nodes), which is consistent with the rate of our hospital (55.9%).

The most widely used international staging system is the TNM by the AJCC. For our study, we used the 7th Edition, which was valid in the period in which the patients of the study underwent surgery, with the following lymph node staging: pN0 in cases without lymph node involvement, pN1 1–2 positive nodes, pN2 3–6 positive nodes and pN3 >6 positive nodes. It should be noted that, in said edition, the pN3 category did not adequately discriminate lymph node disease. In order to reduce this limitation, in 2018 the 8th Edition began to be used, which subdivides the pN3 group into pN3a for cases with 7–15 affected nodes and pN3b for cases with 15 or more affected nodes.1 However, the current TNM system still has several limitations, especially in cases with suboptimal lymphadenectomies, which may imply a ‘stage migration’ effect and, consequently, reduce its prognostic value.9

On the other hand, when analyzing the positive lymph nodes among the total number of resected nodes, the LNR is less affected by the extension of the lymphadenectomies, which would more accurately determine lymph node involvement and help minimize ‘stage migration’. In addition, it would also provide greater precision as an independent prognostic factor.2,3,10,11 In fact, the cohort study published by Kong SH et al. reported that the LNR seemed to be the best predictor of the prognosis.3 However, the great heterogeneity in its different categories, as well as the absence of the theoretical benefit in grade N0 patients, would prevent its general consideration as an alternative to the pN category of the TNM, with NR0 being the same as pN0. That is, its discrimination capacity decreases when the LNR is 0 or 1, and patients with 0/0 or 0/30 and 3/3 or 30/30 positive nodes obtain the same LNR.12,13 Due to these limitations, the LODDS was proposed, which is a system that had been previously used in colon and breast cancers,14,15 and which has also been proposed as an alternative for the staging of gastric cancer.16 Hui J et al. reported the superiority of LODDS compared to LNR and the pN category, as did Sun Z et al, who demonstrated its benefit as a prognostic factor in gastric cancer.17 All this has greater clinical relevance in tumors with more lymph node involvement, such as those with diffuse histology. In the recent publication by Pengfei G et al., the authors state that when the LNR value is limited to 0.2−0.8, both systems (LNR and LODDS) are similar; however, as the LNR value approaches the absolute value of 0 or 1, the LODDS value is heterogeneous, which implies the discriminatory capacity of LODDS in patients with the same LNR.12

In the present study, the 3 classification systems have been compared in order to determine which would be the most appropriate based on its theoretical prognostic value. The 3 systems obtained similar results in the univariate analysis and behaved as independent prognostic factors in the multivariate analysis. It should be noted that the tNR and LODDS systems proved to be better than the pN category in cases with suboptimal lymphadenectomies (44.1% of the subjects studied), with a more favorable AUC for the LODDS. In contrast, the applicability of the latter is tedious and difficult to interpret17 and, therefore, not very feasible for use in routine clinical practice, which does not occur with the calculation of the LNR.

Likewise, for a staging system to be adequate, it should meet several requirements: (1) Monotonicity, meaning that as the stage of the disease increases, survival decreases; (2) Homogeneity, with similar survival rates within each category; and (3) Differentiation, or distinction of survival among the different patient groups.18

After analyzing our data, we have noticed that the TNM is a system with monotonicity and homogeneity; however, it has little discrimination capacity, and the survival curves for pN2 and pN3 overlap at 5 years. The tNR system, on the other hand, has been shown to have the most homogeneous distribution, monotonicity, adequate discriminatory capacity and no overlapping Kaplan–Meier curves. Third, the LODDS turned out to be a system with monotonicity and discrimination capacity, but it did not obtain homogeneous distribution in the sample. Nevertheless, it was the system that presented the highest ROC value (AUC: 0.734), which suggests that it could be the most specific to estimate the prognosis of gastric cancer. But, its calculation and interpretation are complex, both in clinical practice and in research. The LNR, however, is a simpler system that is more widely used among professionals, and both are valid as independent prognostic factors.12 In fact, although we have obtained similar AUC for TNM and LNR in our cohort, various studies, including a meta-analysis published in 2018 by Zhu J et al., recommend the use of LNR as a prognostic factor for lymph node staging in gastric cancer.19 The benefit of its application, which is simpler than the LODDS system,12,13 lies in the fact that its correct interpretation can reduce the ‘stage migration’ effect, which sometimes occurs in patients with insufficient lymph node dissection who are staged using the classical TNM system.5–9

Among the limitations of the study, it is worth mentioning that it is a retrospective single-center series, which may have negative repercussions in terms of higher-level scientific evidence. In addition, another problem that arises is the correct choice of cut-off points to define the different prognostic subgroups.

In closing, we can conclude that lymph node involvement determined by LNR expressed with tertiles has been shown to be an independent prognostic factor for estimating survival in our cohort of patients operated on for gastric cancer, especially in cases with suboptimal lymphadenectomy. However, more prospective, randomized studies are needed to evaluate the efficacy of these lymph node staging systems, assess the feasibility of their application, and even consider the possibility of their inclusion within the TNM system. To this end, the creation of audited prospective registries, such as that of the European Registry of Cancer Care (EURECCA) group,20 could be of interest.


No grants were received to fund this study.

Conflict of interests

The authors have no conflict of interests to declare.

K. Washington.
7-8th Edition of the AJCC Cancer Staging Manual: Stomach.
Ann Surg Oncol, 17 (2010), pp. 3077-3079
C. Jian-hui, C. Shi-rong, W. Hui, C. Si-le, X. Jian-bo, Z. Er-tao, et al.
Prognostic value of three different lymph node staging systems in the survival of patients with gastric cancer following D2 lymphadenectomy.
Tumor Biol., 37 (2016), pp. 11105-11113
R. Persiani, S. Rausei, A. Biondi, S. Boccia, F. Cananzi, D. D´Ugo.
Ratio of metastasic lymph nodes: Impact on staging and survival of gastric cancer.
K. Bouliaris, G. Rachiotis, A. Diamantis, G. Christodoulidis, E. Polychronopoulou, K. Tepetes.
Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system.
EJSO., 43 (2017), pp. 1350-1356
O.C. Kutlu, M. Watchell, S. Dissanaike.
Metastasic lymph node ratio successfully predicts prognosis in western gastric cancer patients.
Surg Oncol., 24 (2015), pp. 84-88
Surgical management of invasive gastric cancer. Up to Date, https://www.uptodate.com/contents/2481 [consultada el 28 de diciembre de 2020].
H. Lui, J. Deng, R. Zhang, X. Hao, X. Jiao, H. Liang.
The RML of lymph node metastasis was superior to th LODDS for evaluating the prognosis of gastric cancer.
Int J Surg., 11 (2013), pp. 419-424
M.Z. Qui, H.J. Qui, Z.Q. Wang, C. Ren, D.S. Wang, D.S. Zang, et al.
The tumor-log odds of positive lymph nodes-metastasis staging system, a promising new staging system for gastric cancer after D2 resection in China.
PLos One., 7 (2012), pp. e31736
Y. Kim, H. Malcolm, G.A. Poultsides, R.C. Fields, S.M. Weber, K.I. Votanopoulos, et al.
Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Surgery., 162 (2017), pp. 285-294
Y.S. Hung, S.C. Chang, K.H. Lui, C.Y. Hung, Y.C. Kuo, C.Y. Tsai, et al.
A prognostic model based on lymph node metastatic ratio for predicting survival outcome in gastric cancer patients with N3b subclassification.
Asian J Surg., 42 (2019), pp. 85-92
S. Pan, P. Wang, Y. Xing, K. Li, Z. Wang, H. Xu, et al.
Retrieved lymph nodes from different anatomic groups in gastric cancer: a proposed optimal number, comparison with other nodal classification strategies and its impact on prognosis.
Cancer Communications, 39 (2019), pp. 1-12
P. Gu, J. Deng, Z. Sun, Z. Wang, W. Wang, H. Liang, H. Xu, Z. Zhou.
Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.
Surg Today., 51 (2021), pp. 101-110
P. Aurello, N. Petrucciani, G.R. Nigri, M. La Torre, P. Magistri, S. Tierno, F. D’Angelo, G. Ramacciato.
Log odds of positive lymph nodes (LODDS): what are their role in the prognostic assessment of gastric adenocarcinoma?.
J Gastrointest Surg, 18 (2014), pp. 1254-1260
L.J. Chen, K. Chung, Y. Chang, Y. Chang.
Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy.
Surg Oncol, 24 (2015), pp. 239-247
R. Persiani, F. Cananci, A. Biondi, G. Paliani, A. Tufo, F. Ferrara, et al.
Log odds positive lymph nodes in colon cancer: a meaningful ratio-based lymph node classification system.
World J Surg., 36 (2012), pp. 667-674
A. Calero, J. Escrig-Sos, F. Mingol, A. Arroyo, D. Martinez-Ramos, M. de Juan, et al.
Usefulness of the log odds of positive lymph nodes to predict and discriminate prognosis in gastric carcinomas.
J Gastrointest Surg, 19 (2015), pp. 813-820
Z. Sun, Y. Xu, M. de Li, Z.N. Wang, G.L. Zhu, B.J. Huang, et al.
Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection.
Cancer, 116 (2010), pp. 2571-2580
T.W. Rice, V.W. Rusch, H. Ishwaran, E.H. Blackstone, G. Poultsides.
Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data driven staging for theseventh edition of American Joint Committee on Cancer/International Union Against Cancer Staging Manuals.
Cancer, 116 (2010), pp. 3763-3773
J. Zhu, Z. Xue, S. Zhang, X. Guo, L. Zhai, S. Shang, et al.
Integrated analysis of the prognostic role of the lymph node ratio in node-positive gastric cancer: a meta-analysis.
Int J Surg., 57 (2018), pp. 76-83
W. Allum, J. Osorio.
EURECCA Oesophago-Gastric Cancer Proyect.

Please cite this article as: Villalabeitia Ateca I, Perfecto Valero A, Serrano Hermosilla C, Marcaida Salazar A, Pérez Fernández S, Sarriugarte Lasarte A. Valor pronóstico del ratio nodal en el cáncer gástrico: análisis unicéntrico de 199 pacientes. Cir Esp. 2022;100:266–273.

Copyright © 2021. AEC
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más